Deciphex
Deciphex is building a global network of AI empowered pathologists, ensuring accessible, innovative pathology services that improve patient outcomes. The pathology industry is beset with increasing caseload and diagnostic complexity, against a globally declining number of pathologists to service the workload. We believe that digital pathology combined with computer aided diagnostic tools will help make pathologists work more efficiently in the future, and offers a solution to the pending crisis in supply/demand in pathology services.
Deciphex
Deciphex is building a global network of AI empowered pathologists, ensuring accessible, innovative pathology services that improve patient outcomes. The pathology industry is beset with increasing caseload and diagnostic complexity, against a globally declining number of pathologists to service the workload. We believe that digital pathology combined with computer aided diagnostic tools will help make pathologists work more efficiently in the future, and offers a solution to the pending crisis in supply/demand in pathology services.
TL;DR
Headquarters: Glasnevin, Dublin, Ireland
Founded: 2017
Core product areas: Diagnexia (clinical diagnostics network), Patholytix (digital pathology workflows & AI)
Latest disclosed round: €31M Series C (Jan 2025)
Total funding (reported): USD 78,100,000 (reported)
Related Companies
| Company |
|---|
 |
 |
 |
 |
 |
Company Overview
Problem Domain
Digital pathology and AI-enabled diagnostic workflows to scale pathology services and support clinical/research needs.
Founded
2017
Industry
Software Development
Funding Track Record
€31,000,000
Announced Jan 2025; participation from ACT Venture Capital, Seroba, Charles River Laboratories, IRRUS Investments, MedTech Syndicates and NextSteps Capital.
$11,500,000
Announced May 2022; participation from Charles River Laboratories, Novartis, IRRUS Investments, NextSteps Capital and others.
Investor Signal
“Molten Ventures led Series C; participation from strategic and life-science investors including ACT Venture Capital, Seroba Life Sciences, Charles River Laboratories and others.”